Maxigen Biotech Inc.

Taiwan Stock Exchange 1783.TW

Maxigen Biotech Inc. Shareholders' Equity for the year ending December 31, 2023: USD 44.34 M

Maxigen Biotech Inc. Shareholders' Equity is USD 44.34 M for the year ending December 31, 2023, a 4.90% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Maxigen Biotech Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 42.27 M, a 2.62% change year over year.
  • Maxigen Biotech Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 41.19 M, a 34.67% change year over year.
  • Maxigen Biotech Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 30.58 M, a 7.46% change year over year.
  • Maxigen Biotech Inc. Shareholders' Equity for the year ending December 31, 2019 was USD 28.46 M, a 3.24% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
SV Wall Street
Taiwan Stock Exchange: 1783.TW

Maxigen Biotech Inc.

CEO Ms. Ching-Ting Chen
IPO Date Oct. 3, 2012
Location Taiwan
Headquarters No. 88, Keji 1st Road
Employees 127
Sector Healthcare
Industries
Description

Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. The company offers Formagraft, a bone graft substitute; Formasetin, a bone void filler; and intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names for use in orthopedic area. It also provides Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental grafts for use in orthopedic and dental areas. In addition, the company offers FormaAid, a collagen membrane; and E-TECH DENTISTAR II sterilizer and disinfectant for use in dental area, as well as HealiAid, a collagen wound dressing product for use in dental and wound dressing area. Further, it provides ophthalmic viscoelastic device under the ViscAid, PreviscAid, and BiVisc names; and Formaderm, a dermal filler injection for use in plastic surgery. Additionally, the company offers skincare products, including face, neck, body, limbs, and other masks; and make up remover, cleansing, exfoliating, toner, essence, men's care, sunscreen, body care, hand/foot care, and special care products. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan City, Taiwan.

StockViz Staff

February 4, 2025

Any question? Send us an email